Physician profile
Robert B Keyser
NPI 1881634301
$533.55
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $96.80 · 2021: $20.49 · 2022: $160.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $92.08 | 2019 | |
| Akorn, INC. | $84.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $65.46 | 2022 | |
| Allergan, INC. | $50.42 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $44.21 | 2019 | |
| Eyevance Pharmaceuticals LLC | $38.33 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $36.05 | 2022 | |
| Alcon Vision LLC | $24.65 | 2022 | |
| Shire North American Group INC | $24.23 | 2019 | |
| Kala Pharmaceuticals, INC. | $22.80 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Mallinckrodt Hospital Products INC. | $16.04 | 2022 | |
| Horizon Therapeutics Plc | $15.58 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Keyser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.